TRPV6 and posterior cortical atrophy: Our data clearly demonstrate the prospective use of a mAb82-like (a humanized version of mAb82 or other TRPV6-targeting mAbs with similar properties) in targeting TRPV6 in vivo in PCa and other malignancies in general where TRPV6 is involved as a cause.